<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841269</url>
  </required_header>
  <id_info>
    <org_study_id>28455</org_study_id>
    <secondary_id>5R01MH058681-06</secondary_id>
    <nct_id>NCT00841269</nct_id>
  </id_info>
  <brief_title>Oral Uridine for Treatment of Bipolar Depression in Adolescents</brief_title>
  <official_title>Oral Administration of Uridine for Treatment of Bipolar Depression in Adolescents: A Magnetic Resonance Spectroscopy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if the investigational medication uridine reduces&#xD;
      depression symptoms in adolescents with bipolar disorder. Uridine is a naturally occurring&#xD;
      chemical that is made by the human liver. Uridine is part of a family of compounds called&#xD;
      pyrimidines, and is normally involved in many of the body's processes such as the use of&#xD;
      energy by cells. Uridine is considered experimental, because it has not been approved by the&#xD;
      U.S. Food and Drug Administration (FDA) to treat bipolar depression in adolescents. The study&#xD;
      will use standard methods of assessing adolescent's mood, such as rating scales and&#xD;
      questionnaires. In addition, the study will use Magnetic Resonance Imaging Spectroscopy&#xD;
      (MRI/MRS) brain scans to see if levels of certain chemicals in the brain change when&#xD;
      adolescents are treated with uridine. These scans use a magnet to create images of the brain,&#xD;
      and do not expose patients to radiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study of the investigational drug uridine in the treatment of&#xD;
      adolescents with depression with bipolar disorder. Uridine has shown positive results in a&#xD;
      Phase II study of bipolar disorder in adults&#xD;
      (http://clinicaltrials.gov/ct2/show/NCT00322764). This study will enroll 30 depressed&#xD;
      adolescent participants who meet DSM-IV-TR criteria for bipolar disorder type I, type II or&#xD;
      bipolar disorder not otherwise specified. Participants who are currently taking psychotropic&#xD;
      medication(s) will continue on their current regimen, with uridine added as adjunctive&#xD;
      therapy. Participants who are untreated will be informed of the alternatives to study&#xD;
      participation. This will include informing the parent(s) or guardian(s) that Lithium,&#xD;
      Risperdal and Abilify are FDA-approved treatments for adolescent bipolar disorder that would&#xD;
      be available to their child in community care.&#xD;
&#xD;
      The study has three objectives: 1) To use Magnetic Resonance Spectroscopy (MRS) brain imaging&#xD;
      to measure levels of beta-nucleoside triphosphate (b-NTP) in the anterior cingulate cortex of&#xD;
      30 adolescents with bipolar disorder, before-and-after 6 weeks of treatment with the&#xD;
      investigational drug uridine; 2) To measure the antidepressant response to uridine in the 30&#xD;
      participants with the Children's Depression Rating Scale (CDRS); and 3) To acquire structural&#xD;
      Magnetic Resonance Imaging (MRI) data in the 30 participants with bipolar disorder and the 30&#xD;
      healthy controls, to establish regionally-specific structure/neurochemical relationships.&#xD;
&#xD;
      Adolescent participants with bipolar disorder will be treated with uridine 500mg twice daily&#xD;
      for six weeks. The primary clinical outcome measure is the Children's Depression Rating Scale&#xD;
      (CDRS), with response defined as a 30% reduction in CDRS score. In addition to this&#xD;
      standardized clinical assessment, participants will undergo magnetic resonance imaging and&#xD;
      magnetic resonance spectroscopy (MRI/MRS) brain scans at baseline, and after six weeks of&#xD;
      treatment with uridine. This novel approach is designed to explore objectively measurable&#xD;
      biomarkers of illness and treatment response in pediatric bipolar disorder. The investigators&#xD;
      hypothesize that participants whose depression responds to uridine will demonstrate an&#xD;
      increased concentration of beta-nucleoside triphosphate (b-NTP) in the anterior cingulate&#xD;
      cortex. This would support the hypothesis that depressive states are associated with&#xD;
      abnormalities in brain energy metabolism.&#xD;
&#xD;
      As a neuroimaging comparison group for the participants with bipolar disorder, 30 healthy&#xD;
      adolescent controls with no history of psychiatric illness will be recruited for MRI/MRS&#xD;
      scanning only. The investigators hypothesize that controls will have higher levels of b-NTP&#xD;
      in the anterior cingulate cortex than participants with depression associated with bipolar&#xD;
      disorder, further supporting a connection between brain bioenergetics and depression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Scores in Children's Depression Rating Scale (CDRS-R), Assessed Before and After 6 Week Uridine Treatment</measure>
    <time_frame>6 weeks</time_frame>
    <description>The CDRS-R is a 17-item scale, with items rated for severity on a 5 point scale for 3 items and on a 7 point scale for 14 items (possible total score from 17 to 113). Ratings are completed by a clinician via interviews with the child or parent. Scores ≥40 are indicative of depression, whereas scores ≤28 is often used to define remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Primary Neuroimaging Outcome Will be Changes in Beta-NTP to TP (Total Phosphorus) Ratio in the Anterior Cingulate.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A Secondary Outcome Measure Includes a Change in Young Mania Rating Scale (YMRS) Score</measure>
    <time_frame>6 weeks</time_frame>
    <description>The Young Mania Rating Scale (YMRS) is an 11-item rating scale that evaluates manic symptoms. Total scores range from 0-60, with higher scores indicating more manic symptoms endorsed by research participants.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Uridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uridine 500 mg by mouth twice daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Comparison</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy comparison participants were seen for baseline and week 6 MRI scans. No treatment was administered to participants enrolled as healthy comparisons.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uridine</intervention_name>
    <description>Uridine 500 mg by mouth twice per day for 6 weeks</description>
    <arm_group_label>Uridine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Selection of Participants with Bipolar Disorder:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must meet DSM-IV-TR (American Psychiatric Association, 2000) criteria for&#xD;
             Bipolar Disorder Type I, Type II, or Not Otherwise Specified (NOS) with current mood&#xD;
             state depressed for &gt; 2 weeks&#xD;
&#xD;
          -  Participants must be between the age of 13 and 18 years&#xD;
&#xD;
          -  Participants who enter the study on psychotropic medications must be on a regimen that&#xD;
             has been stable for &gt; 2 weeks at the time of study entry&#xD;
&#xD;
          -  Participants must be able to give informed consent or assent, and&#xD;
             parent(s)/guardian(s) must be able to give informed permission for study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adolescents with an unstable co-morbid medical, neurological, or psychiatric disorder&#xD;
&#xD;
          -  Pregnant females, nursing mothers, or females of childbearing potential who are unable&#xD;
             or unwilling to practice contraception during the study&#xD;
&#xD;
          -  Participants with high risk of suicidal behaviors, homicidal behaviors, or self-harm&#xD;
&#xD;
          -  Participants who in the opinion of the investigator are unlikely to be able to comply&#xD;
             with the study protocol&#xD;
&#xD;
          -  Participants who meet DSM-IV-TR criteria for current substance abuse or substance&#xD;
             dependence, with the exception of nicotine abuse or dependence&#xD;
&#xD;
          -  Participants for whom the MRI/MRS scans are contraindicated, such as children with&#xD;
             ferromagnetic implants or claustrophobia&#xD;
&#xD;
          -  Participants whose mood state is manic&#xD;
&#xD;
          -  Documented or suspected history of mental retardation (IQ&lt;70)&#xD;
&#xD;
          -  Positive urine drug screen for cocaine or amphetamines&#xD;
&#xD;
          -  Known hypersensitivity to uridine&#xD;
&#xD;
        Selection of Healthy Volunteers:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be between the ages of 13 and 18 years&#xD;
&#xD;
          -  Participants must not meet DSM-IV-TR diagnostic criteria for a mental disorder or&#xD;
             substance abuse&#xD;
&#xD;
          -  Participants must be able to give informed consent or assent and parents/guardians&#xD;
             must be able to give informed permission for participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant medical, neurological, psychiatric or substance abuse disorder&#xD;
&#xD;
          -  Pregnant subjects, due to the unknown effects of MRI/MRS scans on a fetus. In&#xD;
             addition, women of childbearing potential who are unable or unwilling to practice&#xD;
             contraception during the study will be excluded. Female participants who are of&#xD;
             child-bearing potential must have a negative urine pregnancy test before each MRI/MRS&#xD;
             scan.&#xD;
&#xD;
          -  Participants with a contraindication to MRI/MRS scanning, such as a metallic implant&#xD;
&#xD;
          -  Patients unable to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas G Kondo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://UtahBrain.org</url>
    <description>UtahBrain.org</description>
  </link>
  <results_reference>
    <citation>Kondo DG, Sung YH, Hellem TL, Delmastro KK, Jeong EK, Kim N, Shi X, Renshaw PF. Open-label uridine for treatment of depressed adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2011 Apr;21(2):171-5. doi: 10.1089/cap.2010.0054. Epub 2011 Apr 12.</citation>
    <PMID>21486171</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 9, 2009</study_first_submitted>
  <study_first_submitted_qc>February 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <results_first_submitted>December 10, 2014</results_first_submitted>
  <results_first_submitted_qc>January 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2015</results_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Douglas Kondo, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Bipolar Manic Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited via clinician referrals and IRB-approved recruitment materials and advertising.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Open Label Uridine Treatment</title>
          <description>Participants received fixed-dose uridine 500 mg twice daily for 6 weeks. At each treatment visit, the following rating scales were administered: The CDRS-R, YMRS, and the Columbia-Suicide Severity Rating Scale (C-SSRS)</description>
        </group>
        <group group_id="P2">
          <title>Healthy Comparison</title>
          <description>Participants assigned to this group were seen for two scan visits (baseline and week 6). Healthy comparison participants received no intervention.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label Uridine Treatment</title>
          <description>All participants were Caucasian. There were 5 female participants and 2 male participants.</description>
        </group>
        <group group_id="B2">
          <title>Healthy Comparison</title>
          <description>Participants assigned to this group were seen only at baseline and received no intervention.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.05" spread="1.50"/>
                    <measurement group_id="B2" value="15.67" spread="1.84"/>
                    <measurement group_id="B3" value="15.83" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Scores in Children's Depression Rating Scale (CDRS-R), Assessed Before and After 6 Week Uridine Treatment</title>
        <description>The CDRS-R is a 17-item scale, with items rated for severity on a 5 point scale for 3 items and on a 7 point scale for 14 items (possible total score from 17 to 113). Ratings are completed by a clinician via interviews with the child or parent. Scores ≥40 are indicative of depression, whereas scores ≤28 is often used to define remission.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Uridine Treatment</title>
            <description>Participants received fixed-dose uridine 500 mg twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Comparison</title>
            <description>Participants assigned to this group were seen for two scan visits (baseline and week 6). Healthy comparison participants received no intervention/treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Scores in Children's Depression Rating Scale (CDRS-R), Assessed Before and After 6 Week Uridine Treatment</title>
          <description>The CDRS-R is a 17-item scale, with items rated for severity on a 5 point scale for 3 items and on a 7 point scale for 14 items (possible total score from 17 to 113). Ratings are completed by a clinician via interviews with the child or parent. Scores ≥40 are indicative of depression, whereas scores ≤28 is often used to define remission.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" lower_limit="40" upper_limit="82"/>
                    <measurement group_id="O2" value="21.29" lower_limit="17" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after 6 week Uridine treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.83" lower_limit="20" upper_limit="59"/>
                    <measurement group_id="O2" value="20" lower_limit="17" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Primary Neuroimaging Outcome Will be Changes in Beta-NTP to TP (Total Phosphorus) Ratio in the Anterior Cingulate.</title>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Uridine Treatment</title>
            <description>Participants received fixed-dose uridine 500 mg twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Comparison</title>
            <description>Participants assigned to this group were seen for two scan visits (baseline and week 6). Healthy comparison participants received no intervention/treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Neuroimaging Outcome Will be Changes in Beta-NTP to TP (Total Phosphorus) Ratio in the Anterior Cingulate.</title>
          <units>Beta-NTP/TP Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1168" spread="0.0157"/>
                    <measurement group_id="O2" value="0.1232" spread="0.0127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 6 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1193" spread="0.0142"/>
                    <measurement group_id="O2" value="0.1297" spread="0.0140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A Secondary Outcome Measure Includes a Change in Young Mania Rating Scale (YMRS) Score</title>
        <description>The Young Mania Rating Scale (YMRS) is an 11-item rating scale that evaluates manic symptoms. Total scores range from 0-60, with higher scores indicating more manic symptoms endorsed by research participants.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Uridine Treatment</title>
            <description>Participants received fixed-dose uridine 500 mg twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Comparison</title>
            <description>Participants assigned to this group were seen for two scan visits (baseline and week 6). Healthy comparison participants received no intervention/treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>A Secondary Outcome Measure Includes a Change in Young Mania Rating Scale (YMRS) Score</title>
          <description>The Young Mania Rating Scale (YMRS) is an 11-item rating scale that evaluates manic symptoms. Total scores range from 0-60, with higher scores indicating more manic symptoms endorsed by research participants.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.42" lower_limit="2" upper_limit="11"/>
                    <measurement group_id="O2" value="0.7083" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 6 weeks treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O2" value="2.1818" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from participants at every visit, starting after the treatment intervention was dispensed at baseline. Adverse events were assessed up to 6 weeks.</time_frame>
      <desc>Healthy comparison participants were only seen for scans at baseline and week 6. Healthy comparison participants were not exposed to any treatment intervention, therefore, adverse events were not collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Uridine 500 mg by Mouth Twice Daily for 6 Weeks</title>
          <description>Because this was an open-label study, all participants received the investigational drug uridine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <description>A 17 year old male participant had suicide ideation that occurred 2 weeks after he completed the study and stopped the investigational drug. It was determined that this serious adverse event was expected, and not related to the study medication.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramp, Nausea, Indigestion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms (fatigue, bronchitis, sinusitis)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vivid Dreams</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited sample size and small percentage of underrepresented racial/ethnic minority participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Douglas Kondo</name_or_title>
      <organization>University of Utah</organization>
      <phone>(801) 587-1549</phone>
      <email>doug.kondo@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

